Stay updated on Sitravatinib for Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib for Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Sitravatinib for Metastatic Breast Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedAdded a 'Locations' section with a Texas site; the 'Texas Locations' label was removed. The footer policy link 'HHS Vulnerability Disclosure' was removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing Revision: v3.3.1. This is a minor template/version update and does not modify study details or other user-facing content.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1 on the page, with no other observable changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedRemoved the banner about government funding-related information and potential delays; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check58 days agoChange DetectedThe changes are cosmetic UI/layout adjustments and minor wording changes; core trial details such as eligibility criteria, outcomes, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check87 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference4%

Stay in the know with updates to Sitravatinib for Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib for Metastatic Breast Cancer Clinical Trial page.